Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus dexamethasone versus pomalidomide plus dexamethasone in t(11;14)-positive relapsed or refractory multiple myeloma
2017-003838-88Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Venetoclax + dexamethasone with Pomalidomide + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Jun 2018; status: completed.
02
Drugs
venetoclaxpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-003838-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003838-88.